RAD-SG: Adaptive radiation therapy with concurrent sacituzumab govitecan (SG) for bladder preservation in patients (pts) with muscle invasive bladder cancer (MIBC). A phase 2/3 study of bicycle toxin ...

Since March 2025, the adoption of neoadjuvant and adjuvant immunotherapy-based regimens have shifted the traditional paradigm of cisplatin-based neoadjuvant chemotherapy (NAC) followed by radical ...

The device remains in the bladder and provides a sustained release of gemcitabine throughout the day. The Food and Drug Administration (FDA) has granted Priority Review to TAR-200 for the treatment of ...

Durvalumab plus gemcitabine and cisplatin significantly improved event free survival and overall survival compared with gemcitabine and cisplatin. The Food and Drug Administration (FDA) has approved ...

Gross hematuria in a younger adult prompted rapid urologic evaluation, underscoring that bladder cancer can present before ...

Marking Techniques for Target Lymph Nodes in Node-Positive Breast Cancer Treated With Neoadjuvant Therapy in the AXSANA/EUBREAST-03/AGO-B-053 Study Adults with Eastern Cooperative Oncology Group ...

100% (n=7) of evaluable patients (1 CIS, 6 Ta/T1) achieved disease free status. One of these patients was re-treated at 3 months. “I am impressed by these promising NDV-01 data reported at AUA2025.

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca’s IMFINZI ® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after ...

Perioperative durvalumab with neoadjuvant chemotherapy in muscle-invasive bladder cancer maintains patient-reported outcomes, as shown in the NIAGARA trial. Health-related quality of life was assessed ...